Valence ロゴ
人気
ログイン
Loading data for INDV — first visit, this takes a few seconds.

ウォッチリストに追加

Indivior Pharmaceuticals ...

NasdaqGS: INDV · リアルタイム株価 · USD
34.87
-0.43 (-1.22%)
終値時点： Aug 28, 2026, 3:59 PM
34.87
+0.00%
時間外: 7:30 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Indivior Pharmaceuticals Inc.（INDV）の株価・分析・データ

-1.22%
買気配34.63
時価総額4.12B
売上高（TTM）1.33B
純利益（TTM）356M
1.14
2.75
12.68
7.14
PBR（TTM）-19.78
PSR（TTM）3.09
決算発表日Nov 5, 2026
売気配34.54
出来高2,204,669
平均出来高（20日）2,038,166
始値35.31
前日終値35.30
当日レンジ34.50 - 35.49
52週レンジ22.22 - 42.81
アナリストn/a
目標株価n/a
配当n/a
権利落ち日2016年6月16日

INDVについて

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; a...

[続きを読む]
業種 Drug Manufacturers - Specialty & Generic
セクター Healthcare
IPO日 Dec 29, 2014
従業員数 827
上場取引所 NasdaqGS
ティッカー INDV
ウェブサイト https://www.indivior.com
企業情報の全文

業績

2025年のIndivior Pharmaceuticalsの売上高は1.24Bで、前年の1.19Bから4.29%の増加でした。 利益は210Mで、2,900%の増加でした。

財務諸表

決算サプライズ

Indivior PharmaceuticalsはAug 3, 2026に四半期決算を発表しました：
  • 売上高は $343M で、予想を下回りました $0, うち 13.58% の前年比増加にあたります.
  • EPSは 1.15 で、予想を上回りました 0.23, うち 125.49% の前年比増加にあたります.

次回決算発表

Indivior Pharmaceuticals Inc.の決算発表予定日は Nov 5, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード
news image

1週間前 · Simply Wall St.

Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan

Indivior Pharmaceuticals (INDV) recently drew investor attention after a period of mixed share performance, with the stock down 9% over the past month but still higher year to date. This move has prom...

news image

1週間前 · Zacks

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

news image

1週間前 · Zacks

Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?

Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.

news image

2週間前 · Zacks

Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"

Indivior Pharmaceuticals Inc. (INDV) possesses solid growth attributes, which could help it handily outperform the market.

news image

3週間前 · Zacks

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

2ページ中1ページ